Drug Approval | July 24, 2023
Lupin receives tentative USFDA’s approval for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets
This product would be manufactured at Lupin's Nagpur facility in India
This product would be manufactured at Lupin's Nagpur facility in India
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
The maker of ivermectin/pyrantel, the #1 vet-recommended and #1 dog-preferred real beef chew introduces the latest innovation in its portfolio
Good momentum in commercial CDMO business
The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
Subscribe To Our Newsletter & Stay Updated
